ANDA 219231, held by Dr. Reddy's Laboratories. Carbidopa, Levodopa.
As of Nov 21, 2026, ANDA 219231 (Carbidopa and Levodopa), held by Dr. Reddy's Laboratories, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 18, 2026 | Original application | Tentative approval | None posted |
| Carbidopa and Levodopa145MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa and Levodopa23.75 · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa and Levodopa95MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa and Levodopa245MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa and Levodopa61.25MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa and Levodopa48.75MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa and Levodopa195MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters